← back to search

K Gecse

University Medical Center · NL
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Biosimilars and Bioanalytical Methods, and Diverticular Disease and Complications.
h-index
45
citations
7,855
works
353
NIH funding
primary concept
Medicine
email

Recent publications

Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
˜The œLancet. Gastroenterology & hepatology 2025cited by 7position: middledoi
Ulcerative colitis: moving beyond the mucosal dogma
˜The œLancet. Gastroenterology & hepatology 2025cited by 5position: middledoi
Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program.
2025cited by 4position: contributordoi
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study
Digestive Diseases and Sciences 2025cited by 2position: middledoi
Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response.
2025cited by 0position: contributordoi
Psychometric Development and Internal Validation of a Short Version of the Crohn's Anal Fistula Quality of Life Scale.
2025cited by 0position: contributordoi
Perianal Fistulizing Crohn’s Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme
Journal of Crohn s and Colitis 2024cited by 18position: middledoi
Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease
Clinical Gastroenterology and Hepatology 2024cited by 10position: middledoi
S1437 Pregnancy Outcomes in the Etrasimod Clinical Program
The American Journal of Gastroenterology 2024cited by 8position: firstdoi
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
2024cited by 8position: contributordoi
Classifying Inflammation on Intestinal Ultrasound Images and Cineloops - A Learning Curve Study.
2024cited by 4position: contributordoi
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials
˜The œLancet. Gastroenterology & hepatology 2022cited by 137position: middledoi
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Gastroenterology 2022cited by 109position: lastdoi
Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement.
2022cited by 109position: contributordoi
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
2022cited by 81position: contributordoi
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives.
2022cited by 64position: contributordoi
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
2022cited by 60position: contributordoi
Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients.
2022cited by 41position: contributordoi
Intestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease.
2022cited by 35position: contributordoi
Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm.
2022cited by 33position: contributordoi
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.
2022cited by 28position: contributordoi
The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.
2022cited by 27position: contributordoi
Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT-TOPIC trial after 1-year follow-up.
2022cited by 26position: contributordoi
Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper
Journal of Crohn s and Colitis 2022cited by 25position: lastdoi
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence.
2022cited by 9position: contributordoi
A Healthcare Physician Can Be Trained to Perform Intestinal Ultrasound in Children With Inflammatory Bowel Disease.
2022cited by 8position: contributordoi
Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series.
2022cited by 7position: contributordoi
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.
2022cited by 3position: contributordoi
'Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a Novel UC-Ultrasound Index'.
2022cited by 1position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Mark Löwenberg · Amsterdam University Medical Centers16 papers (2019–2025)Gert De Hertogh · Spaarne Gasthuis6 papers (2016–2025)Johan Burisch · Rigshospitalet6 papers (2017–2024)Jaap Stoker · Stichting Kinderoncologie Nederland6 papers (2014–2025) · 5 papers (2024–2025)Séverine Vermeire · Europe Hospitals5 papers (2015–2025)Marietta Iacucci · University College Cork4 papers (2021–2021)Edoardo Savarino · Amsterdam University Medical Centers4 papers (2021–2021)Jeanin E. van Hooft · Loyola University Medical Center4 papers (2021–2021)Raf Bisschops · RELX Group (Netherlands)4 papers (2021–2021)Peter Bossuyt · Nutrition-Génétique et Exposition aux Risques Environnementaux4 papers (2020–2022)Ailsa Hart · St. Mark's Hospital4 papers (2014–2022)Laurent Peyrin‐Biroulet · Hôpital Lapeyronie4 papers (2019–2025)Geert D’Haens · Vrije Universiteit Amsterdam4 papers (2014–2025)Rune Wilkens · Copenhagen University Hospital3 papers (2022–2024)Peter Irving · Imperial College London3 papers (2019–2022)Robert V. Bryant · Queen Elizabeth Hospital3 papers (2021–2022)Peter M. Irving · Guy's and St Thomas' NHS Foundation Trust3 papers (2022–2025)Frank Hoentjen · Radboud Institute for Molecular Life Sciences3 papers (2021–2025)Mark Samaan · St Thomas' Hospital3 papers (2022–2025)